Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
2021 · New England Journal of Medicine · 2,545 citations
https://doi.org/10.1056/nejmoa2101544
H
Hanneke Schuitemaker
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
455
Papers
30.4K
Citations
88
h-index
294
i10-index
Hanneke Schuitemaker is an academic researcher from Johnson & Johnson (Israel). The author has contributed to research in topics: HIV Research and Treatment & HIV/AIDS drug development and treatment & Immune Cell Function and Interaction. The author has an h-index of 88, co-authored 387 publications.
ORCID: 0000-0001-8563-2266Papers by this author
worksAd26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
2020 · npj Vaccines · 367 citations
https://doi.org/10.1038/s41541-020-00243-x
Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes
2015 · Cell · 366 citations
https://doi.org/10.1016/j.cell.2015.11.056
Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters
2020 · Nature Medicine · 319 citations
https://doi.org/10.1038/s41591-020-1070-6
Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load
2015 · Proceedings of the National Academy of Sciences · 189 citations
https://doi.org/10.1073/pnas.1514867112
Clinical significance of HIV-1 coreceptor usage
2011 · Journal of Translational Medicine · 104 citations
https://doi.org/10.1186/1479-5876-9-s1-s5
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat